申请人:VICHEM CHEMIE KUTATÓ KFT.
公开号:US20160194291A1
公开(公告)日:2016-07-07
The present invention relates to styryl quinazoline derivatives of the general formula (I) and pharmaceutically acceptable solvates, hydrates, salts, regioisomeric and polymorphic forms thereof as well as pharmaceutical compositions containing at least one of the described compounds as pharmaceutically active agent. The compounds have been identified as new drug candidates for the prevention and/or treatment of diseases related to disfunction(s) of hematopoiesis and cancer or any other form of neo- or hyperplasias related to Fms-like tyrosine kinase 3 (FLT3) containing Internal Tandem Duplications (ITD), especially in the case of myeloid leukemia. The compounds have been also identified as new drug candidates as antibacterial agents (having bactericidal or bacteriostatic activity) which can be used for the prevention and/or treatment of bacterial infectious diseases.
本发明涉及一般式(I)的苯乙烯基喹唑啉衍生物及其药学上可接受的溶剂化物、水合物、盐、区域异构体和多晶形式,以及包含所述化合物中至少一种作为药学活性剂的制药组合物。这些化合物已被确定为新药候选物,用于预防和/或治疗与造血功能障碍和癌症或与含有内部串联重复(ITD)的Fms样酪氨酸激酶3(FLT3)相关的任何形式的新生或增生有关的疾病,特别是髓系白血病的情况。这些化合物还被确定为新的抗菌剂(具有杀菌或抑菌活性),可用于预防和/或治疗细菌感染性疾病。